Furthermore, CDK9 inhibition by dinaciclib treatment has been shown to induce apoptotic responses in aggressive MYC-driven B-cell lymphoma through transcriptional blockage of MCL-133. Here, CDK9 is linked to B-cell non-Hodgkin lymphoma.